A phase I trial of intra-arterial delivery of SL 052 photodynamic therapy in patients with localised prostate cancer.

Trial Profile

A phase I trial of intra-arterial delivery of SL 052 photodynamic therapy in patients with localised prostate cancer.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Nov 2011

At a glance

  • Drugs SL 052 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Quest PharmaTech
  • Most Recent Events

    • 29 Nov 2011 Status changed from planning to recruiting, according to a Quest PharmaTech media release.
    • 11 May 2010 Planned number of patients changed from 12 to 18 according to Quest PharmaTech media release.
    • 11 May 2010 According to a company media release, Quest PharmaTech has begun dosing of the first patient in this Phase I clinical trial of SL052 Photodynamic Therapy in prostate cancer patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top